VRTX · Vertex Pharmaceuticals Incorporated
$491.342026-07-21Sector: Healthcare; Industry: Biotechnology; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr) · Leases factoredBase · active
$502
+2.2% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($406 · $742) Analysts Range ($436 · $616) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $9.9B | — | 48.3% | 15.7% | $4.0B | −$2.7B | $1.3B | 5.5% | — | 21.4% | $18.8B | $14.12 | — |
| 2024.Q4 | $9.9B | 0.0% | 48.3% | 45.0% | $2.6B | −$3.1B | −$436MM | 6.2% | — | 13.2% | $20.8B | $14.12 | — |
| 2025.Q1 | $11.0B | 11.7% | -2.1% | 0.0% | −$767MM | −$1.9B | −$2.7B | 5.8% | — | -3.7% | $20.6B | $-2.09 | — |
| 2025.Q4 | $11.0B | 0.0% | -2.1% | 14.9% | −$198MM | −$2.3B | −$2.5B | 5.9% | — | -0.9% | $24.3B | $-2.09 | — |
| 2026.Q1 | $12.3B | 11.2% | 48.4% | 16.0% | $5.0B | −$3.8B | $1.2B | 5.5% | — | 20.4% | $24.6B | $16.93 | 21.2 |
| italics below = DCF projection · 10yr Rev CAGR: 8.4% |
| 2027.Q1 | $13.3B | +8.9% | 49.4% | 16.4% | $5.5B | −$2.2B | $3.3B | 5.8% | $3.1B | 21.4% | $26.8B | $17.29 | 28.4 |
| 2028.Q1 | $14.7B | +9.8% | 50.1% | 16.8% | $6.1B | −$2.7B | $3.4B | 6.0% | $3.0B | 21.7% | $29.5B | $19.17 | 25.6 |
| 2029.Q1 | $16.3B | +10.9% | 50.1% | 17.2% | $6.7B | −$3.4B | $3.4B | 6.3% | $2.8B | 21.6% | $32.9B | $21.17 | 23.2 |
| 2030.Q1 | $18.0B | +10.8% | 54.9% | 17.6% | $8.2B | −$3.8B | $4.4B | 6.6% | $3.4B | 23.4% | $36.7B | $25.61 | 19.2 |
| 2031.Q1 | $19.9B | +10.4% | 54.9% | 18.0% | $9.0B | −$4.1B | $4.9B | 6.9% | $3.6B | 23.1% | $40.8B | $28.13 | 17.5 |
|
| Term. Yr+ | $28.5B | 4.1% | 40.6% | 20.0% | $9.3B | −$2.3B | $7.0B | 8.6% | $78.6B | 16.6% | — | — | — |
Active scenario IV: $502 (+2.2% vs market)